Patents by Inventor Mark T. Edgar

Mark T. Edgar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF MANUFACTURING A SOLID FORM OF A BET BROMODOMAIN INHIBITOR
    Publication number: 20250034142
    Abstract: The invention relates to solid crystalline forms of Compound (I), such as e.g., Form VII, including pharmaceutical compositions thereof and processes for preparing crystalline Compound (I), Form VII. Compound (I) modulates or inhibits the activity of BET bromodomain-containing proteins, and is useful in the treatment of diseases such as cancer, inflammatory and cardiovascular diseases.
    Type: Application
    Filed: October 9, 2024
    Publication date: January 30, 2025
    Inventors: FENG WEN, JIAHUI CHEN, XIANGHUI WEN, MARK T. EDGAR, HENRIK C. HANSEN
  • Method of manufacturing a solid form of a BET bromodomain inhibitor
    Patent number: 12145932
    Abstract: The invention relates to solid crystalline forms of Compound (I), such as e.g., Form VII, including pharmaceutical compositions thereof and processes for preparing crystalline Compound (I), Form VII. Compound (I) modulates or inhibits the activity of BET bromodomain-containing proteins, and is useful in the treatment of diseases such as cancer, inflammatory and cardiovascular diseases.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: November 19, 2024
    Assignee: ZENITH EPIGENETICS LTD.
    Inventors: Feng Wen, Jiahui Chen, Xianghui Wen, Mark T. Edgar, Henrik C. Hansen
  • METHOD OF MANUFACTURING A SOLID FORM OF A BET BROMODOMAIN INHIBITOR
    Publication number: 20220048905
    Abstract: The invention relates to solid crystalline forms of Compound (I), such as e.g., Form VII, including pharmaceutical compositions thereof and processes for preparing crystalline Compound (I), Form VII. Compound (I) modulates or inhibits the activity of BET bromodomain-containing proteins, and is useful in the treatment of diseases such as cancer, inflammatory and cardiovascular diseases.
    Type: Application
    Filed: September 13, 2019
    Publication date: February 17, 2022
    Inventors: FENG WEN, JIAHUI CHEN, Xianghui WEN, MARK T. EDGAR, HENRIK C. HANSEN
  • Tianeptine oxalate salts and polymorphs
    Patent number: 10946027
    Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: March 16, 2021
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar
  • TIANEPTINE OXALATE SALTS AND POLYMORPHS
    Publication number: 20200276208
    Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
    Type: Application
    Filed: October 9, 2019
    Publication date: September 3, 2020
    Inventors: Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar
  • Tianeptine oxalate salts and polymorphs
    Patent number: 10449203
    Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: October 22, 2019
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar
  • TIANEPTINE OXALATE SALTS AND POLYMORPHS
    Publication number: 20180338984
    Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
    Type: Application
    Filed: December 28, 2017
    Publication date: November 29, 2018
    Inventors: Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar